All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge, UZ Leuven, Leuven, BE. We asked, What are the future prospects and access to advanced immunotherapies for multiple myeloma (MM) in Europe?
Access and future prospects of advanced immunotherapies for multiple myeloma in Europe
In this video, Delforge explains the current treatment options for advanced refractory MM, comparing anti-BCMA CAR-T therapy with bispecific antibody therapy. Delforge also mentions both ciltacabtagene autoleucel (cilta-cel) and the CARTITUDE-1 trial (NCT03548207), and idecabtagene vicleucel (ide-cel) and the KarMMa trial (NCT03361748). Delforge highlights the importance of patient responses and overall survival rates, as well as considering the limited access to anti-BCMA CAR-T cells as an area of unmet patient need.
ASH 2021 abstracts: What’s hot in multiple myeloma?
To help navigate the exciting content being presented at the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the...
Editorial theme | Neurotoxicity and anti-BCMA agents
Chimeric antigen receptor (CAR) T-cell therapy (CAR-T) and bispecific antibodies represent two novel immunotherapeutic treatment modalities in the relapsed/refractory (R/R) setting of multiple...
Subscribe to get the best content related to multiple myeloma delivered to your inbox